1,271
Views
45
CrossRef citations to date
0
Altmetric
Research Article

Mechanism of Polysaccharides from Dendrobium huoshanense. on Streptozotocin-Induced Diabetic Cataract

, &
Pages 243-249 | Accepted 31 Aug 2007, Published online: 07 Oct 2008

Figures & data

Table 1 Sequences of the primers used in RT-PCR.

Table 2 Comparison of weight and blood sugar of rats after feeding for 45 days.

Figure 1 HPS retards the progression of diabetic cataract in vivo. in rats. (A) Normal rat eyes; (B) Generation of cataract in rat in vivo. by the administration of STZ without therapy; (C, D, E) the eyes of rats in 50 mg kg− 1day− 1, 100 mg kg− 1day− 1, and 200 mg kg− 1day− 1 HPS-treated groups, respectively.

Figure 1 HPS retards the progression of diabetic cataract in vivo. in rats. (A) Normal rat eyes; (B) Generation of cataract in rat in vivo. by the administration of STZ without therapy; (C, D, E) the eyes of rats in 50 mg kg− 1day− 1, 100 mg kg− 1day− 1, and 200 mg kg− 1day− 1 HPS-treated groups, respectively.

Table 3 The comparison of the NO content and NOS activities of lens epithelium cells in different groups at 45 days.

Figure 2 RT-PCR analysis using Multicolor Real time PCR Detection system. (A) The real-time PCR amplification chart of iNOS. (B) The real-time PCR amplification chart of β-actin. (C) The real-time melt peak chart of iNOS. NC, normal control; DC, diabetic control; I, group of 50 mg kg− 1day− 1; II, group of 100 mg kg− 1day− 1; III, group of 200 mg kg− 1day− 1.

Figure 2 RT-PCR analysis using Multicolor Real time PCR Detection system. (A) The real-time PCR amplification chart of iNOS. (B) The real-time PCR amplification chart of β-actin. (C) The real-time melt peak chart of iNOS. NC, normal control; DC, diabetic control; I, group of 50 mg kg− 1day− 1; II, group of 100 mg kg− 1day− 1; III, group of 200 mg kg− 1day− 1.

Figure 3 mRNA levels of iNOS in rat lens treated with different concentrations of HPS detected by gelose gel electrophoresis. 1, diabetic cataract control group; 2, 50 mg kg− 1day− 1 HPS-treated group; 3, 100 mg kg− 1day− 1 HPS-treated group; 4, 200 mg kg− 1day− 1 HPS-treated group; 5, normal control group. β-Actin expression at different treated groups is almost the same as that shown in the figure.

Figure 3 mRNA levels of iNOS in rat lens treated with different concentrations of HPS detected by gelose gel electrophoresis. 1, diabetic cataract control group; 2, 50 mg kg− 1day− 1 HPS-treated group; 3, 100 mg kg− 1day− 1 HPS-treated group; 4, 200 mg kg− 1day− 1 HPS-treated group; 5, normal control group. β-Actin expression at different treated groups is almost the same as that shown in the figure.

Table 4 The iNOS C.t., β-actin C.t. and opposite C.t.in different treatment groups.

Figure 4 The fluorescence intensity of AGEs (F-AGEs) in different treatment groups. Data are presented as the means ± standard deviations for three independent experiments. NC, normal control; DC, diabetic control. Group I, 50 mg kg− 1day− 1; group II: 100 mg kg− 1day− 1; group III, 200 mg kg− 1day− 1. The data with different letters in the same item indicate significant difference at p = 0.05.

Figure 4 The fluorescence intensity of AGEs (F-AGEs) in different treatment groups. Data are presented as the means ± standard deviations for three independent experiments. NC, normal control; DC, diabetic control. Group I, 50 mg kg− 1day− 1; group II: 100 mg kg− 1day− 1; group III, 200 mg kg− 1day− 1. The data with different letters in the same item indicate significant difference at p = 0.05.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.